SG11202106912WA - Anti-ephrin-b2 blocking antibodies for the treatment of fibrotic diseases - Google Patents

Anti-ephrin-b2 blocking antibodies for the treatment of fibrotic diseases

Info

Publication number
SG11202106912WA
SG11202106912WA SG11202106912WA SG11202106912WA SG11202106912WA SG 11202106912W A SG11202106912W A SG 11202106912WA SG 11202106912W A SG11202106912W A SG 11202106912WA SG 11202106912W A SG11202106912W A SG 11202106912WA SG 11202106912W A SG11202106912W A SG 11202106912WA
Authority
SG
Singapore
Prior art keywords
ephrin
treatment
fibrotic diseases
blocking antibodies
antibodies
Prior art date
Application number
SG11202106912WA
Inventor
David Lagares
Original Assignee
Massachusetts Gen Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Massachusetts Gen Hospital filed Critical Massachusetts Gen Hospital
Publication of SG11202106912WA publication Critical patent/SG11202106912WA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/48—Other medical applications
    • A61B5/4836—Diagnosis combined with treatment in closed-loop systems or methods
    • A61B5/4839—Diagnosis combined with treatment in closed-loop systems or methods combined with drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/48—Other medical applications
    • A61B5/4842—Monitoring progression or stage of a disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/05—Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves 
    • A61B5/055—Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves  involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biomedical Technology (AREA)
  • Medical Informatics (AREA)
  • Surgery (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
SG11202106912WA 2018-12-28 2019-12-27 Anti-ephrin-b2 blocking antibodies for the treatment of fibrotic diseases SG11202106912WA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862785873P 2018-12-28 2018-12-28
PCT/US2019/068746 WO2020140036A1 (en) 2018-12-28 2019-12-27 Anti-ephrin-b2 blocking antibodies for the treatment of fibrotic diseases

Publications (1)

Publication Number Publication Date
SG11202106912WA true SG11202106912WA (en) 2021-07-29

Family

ID=71127301

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202106912WA SG11202106912WA (en) 2018-12-28 2019-12-27 Anti-ephrin-b2 blocking antibodies for the treatment of fibrotic diseases

Country Status (8)

Country Link
US (1) US20220064285A1 (en)
EP (1) EP3902460A4 (en)
JP (1) JP2022516611A (en)
KR (1) KR20210110326A (en)
AU (1) AU2019414947A1 (en)
CA (1) CA3125160A1 (en)
SG (1) SG11202106912WA (en)
WO (1) WO2020140036A1 (en)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ549787A (en) * 2004-03-12 2010-05-28 Vasgene Therapeutics Inc Antibodies binding to EphB4 for inhibiting angiogenesis and tumor growth
CA2585703A1 (en) * 2004-10-27 2006-05-04 Medimmune Inc. Modulators of epha2 and ephrina1 for the treatment of fibrosis-related disease
AU2008260498B2 (en) * 2007-05-30 2012-11-29 Xencor, Inc. Methods and compositions for inhibiting CD32b expressing cells
WO2008156642A1 (en) * 2007-06-15 2008-12-24 Vasgene Therapeutics, Inc. Non-immunoglobulin antigen binding scaffolds for inhibiting angiogenesis and tumor growth
ES2378976B1 (en) * 2010-09-21 2013-05-06 Fundación Centro Nacional De Investigaciones Oncológicas (Cnio) ANTIBODY AGAINST EPHRIN B2 AND ITS USE.
US9480449B2 (en) * 2012-05-03 2016-11-01 Fibrogen, Inc. Methods for treating idiopathic pulmonary fibrosis
WO2017015720A1 (en) * 2015-07-30 2017-02-02 Monash University Fibrotic treatment

Also Published As

Publication number Publication date
KR20210110326A (en) 2021-09-07
AU2019414947A1 (en) 2021-07-15
JP2022516611A (en) 2022-03-01
EP3902460A1 (en) 2021-11-03
US20220064285A1 (en) 2022-03-03
EP3902460A4 (en) 2023-01-11
CA3125160A1 (en) 2020-07-02
WO2020140036A1 (en) 2020-07-02

Similar Documents

Publication Publication Date Title
IL279260A (en) Kdm1a inhibitors for the treatment of disease
GB201804514D0 (en) Treatment of pyroptosis
IL277861A (en) Axl-specific antibodies for cancer treatment
IL274766A (en) Humanized anti-liv1 antibodies for the treatment of breast cancer
SG11202006374VA (en) Treatment of demyelinating diseases
IL281449A (en) Anti-ifnar1 antibodies for treating autoimmune diseases
ZA201906213B (en) Compounds and methods for the treatment of parasitic diseases
EP3630101A4 (en) Methods for treatment of fibrotic diseases
GB201813876D0 (en) Treatment
IL268357A (en) Photoreceptor cells for the treatment of retinal diseases
IL276482A (en) Compounds for the treatment of pain
IL272937A (en) Compositions and methods for the treatment of fibrotic diseases
SG11202011117VA (en) Treatment of cancer
GB201804515D0 (en) Treatment of necroptosis
IL289842A (en) Humanized anti-liv1 antibodies for the treatment of cancer
GB202015959D0 (en) Treatment of diseases involving NAD
GB201805100D0 (en) Treatment of sarcopenic diseases
ZA202104357B (en) Monoclonal antibodies against the beta chain region of human trbv9
IL281839A (en) Treatment methods
IL281792A (en) Treatment methods
EP3958754C0 (en) Device for the treatment of haemorrhoidal disease
SG11202011434SA (en) Methods for the treatment of bladder cancer
EP3735423A4 (en) Monoclonal antibody neo-201 for the treatment of human carcinomas
GB201808575D0 (en) Methods for the treatment of psoriatic arthrits
IL282361A (en) Treatment of neurological diseases